Monograph Details
|
|
Endocrine System
> Diabetes
|
|
STARLIX |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Insulin secretagogue (amino acid deriv.). |
| Generic Name |
|
Nateglinide 60mg, 120mg; tabs. |
| Indications |
|
Adjunct to diet and exercise in type 2 diabetes, alone (in patients who have not been chronically treated with other antidiabetic agents) or in combination with metformin or a thiazolidinedione. |
| Children |
|
Not recommended. |
| Adults |
|
Take 1–30 minutes before meals; skip dose if meal is skipped. 120mg 3 times daily. If near HbA1C goal, initially 60mg 3 times daily. |
| Contraindications |
|
Type 1 diabetes. Ketoacidosis. |
| Precautions |
|
Moderate to severe hepatic disease. Secondary failure may occur in prolonged therapy. Elderly, adrenal or pituitary insufficiency, stress, strenuous exercise, autonomic neuropathy, severe renal impairment, malnourished: increased risk of hypoglycemia. Labor & delivery. Pregnancy (Cat.C), nursing mothers: not recommended. |
| Interactions |
|
May be potentiated by salicylates, non-cardioselective β-blockers, NSAIDs, alcohol, MAOIs. May be antagonized by thiazides, corticosteroids, sympathomimetics, thyroid products. Monitor with highly protein-bound drugs. Liquid meals reduce peak levels. β-blockers mask hypoglycemia. |
| Adverse Reactions |
|
Hypoglycemia, GI upset with metformin, peripheral edema with rosiglitazone. |
| How Supplied |
|
Tabs—100, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
